Skip to main content

Client News

Apogenix’ partner CANbridge announces 67 % five-year overall survival rate compared to 8.2 % in institutional database with asunercept plus standard of care in newly diagnosed glioblastoma multiforme patients

27th March 2023

Destiny Pharma announces publication of XF-73 nasal gel Phase 2 data in leading US journal Infection Control & Hospital Epidemiology

24th March 2023

Heidelberg Pharma concludes very successful financial year 2022 and reports on course of business

24th March 2023

InflaRx reports full year 2022 financial and operating results

22nd March 2023

A new prestigious scientific publication for Carbios marks the expansion of its research to other plastics

21st March 2023

Mainz Biomed to present at Sidoti Virtual Investor Conference March 22-23

21st March 2023

Rentschler Biopharma’s service excellence recognized with CDMO Leadership Awards and Champion status

20th March 2023

Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia

20th March 2023

Andera Partners co-leads $25m extension round for FIRE1, an Irish medtech developing breakthrough technology for patients with heart failure

15th March 2023

Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany

15th March 2023